(Updates with Biogen's response in the third paragraph and the latest stock moves in the last paragraph.)
Sage Therapeutics (SAGE) said Monday its board rejected Biogen's (BIIB) unsolicited, non-binding proposal to acquire Sage shares not already owned by Biogen for $7.22 per share.
Sage also said its board has started a process to look into strategic alternatives, including a potential business combination or sale. The company said there's no assurance that the review would lead to a transaction or other strategic outcome.
Biogen declined to comment when contacted by MT Newswires.
Sage shares were up 4.7% and Biogen's shares were up 1.9% in recent trading.
Price: 7.44, Change: +0.34, Percent Change: +4.72
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.